Immuron (IMRN) Cash from Investing Activities (2016 - 2024)
Immuron's (IMRN) quarterly Cash from Investing Activities came in at $35309.1 in Q4 2024, down 64.67% year-on-year from $99932.2 in Q1 2024, and down 64.67% quarter-over-quarter from $99932.2 in Q4 2023.
Immuron (IMRN) Cash from Investing Activities (2016 - 2024) Analysis & Trends
Immuron's Cash from Investing Activities history runs 9 years deep, the most recent figure standing at $35309.1 for Q4 2024.
- On a quarterly basis, Cash from Investing Activities fell 64.67% year-over-year to $35309.1 in Q4 2024; TTM through Dec 2024 was -$2.5 million, a 1.43% increase from a year earlier, with the FY2025 full-year figure at -$2.9 million, down 985.46% from the prior year.
- Cash from Investing Activities fell to $35309.1 in Q4 2024 per IMRN's latest filing, from $99932.2 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $99932.2 in Q4 2023 and bottomed at -$2.6 million in Q4 2022.
- The 5-year median for Cash from Investing Activities is $5550.2 (2021), against an average of -$492615.7.
- Across the five-year window, Cash from Investing Activities surged 1943.91% in 2021 and slumped 47009.79% in 2022, its largest moves.
- Year by year, Cash from Investing Activities stood at -$301.0 in 2020, then jumped by 1943.91% to $5550.2 in 2021, then slumped by 47009.79% to -$2.6 million in 2022, then jumped by 103.84% to $99932.2 in 2023, then plunged by 64.67% to $35309.1 in 2024.
- Per Business Quant, the three latest IMRN Cash from Investing Activities figures stand at $35309.1 (Q4 2024), $99932.2 (Q4 2023), and -$2.6 million (Q4 2022).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 172.62 Mn |
| 10 | Immuron | 255.19 Mn | 243.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 35,309.08 |
| Dec 31, 2024 | 35,309.08 |
| Dec 31, 2023 | 99,932.25 |
| Dec 31, 2023 | 99,932.25 |
| Dec 31, 2022 | -2.60 Mn |
| Dec 31, 2022 | -2.60 Mn |
| Dec 31, 2021 | 5,550.16 |
| Dec 31, 2021 | 5,550.16 |
| Dec 31, 2020 | -301.00 |
| Dec 31, 2020 | -301.00 |
| Dec 31, 2019 | -605.00 |
| Dec 31, 2019 | -605.00 |
| Dec 31, 2018 | 39.00 |
| Dec 31, 2018 | 39.00 |
| Dec 31, 2017 | -1,698.97 |
| Dec 31, 2017 | -1,698.97 |
| Dec 31, 2016 | 1,416.72 |
| Dec 31, 2016 | 1,416.72 |